KRAS mutations, the most common type of driver mutation in lung cancer, often found in individuals with a history of smoking, have recently been targeted by sotorasib, a new agent directed at KRAS G12C mutations, showing a response rate of 32% in clinical trials [9]. This evidence concerns the gene KRAS and lung carcinoma.